3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background and Aims

          Coexisting atrial fibrillation (AF) and cancer challenge the management of both. The aim of the study is to comprehensively provide the epidemiology of coexisting AF and cancer.

          Methods

          Using Dutch nationwide statistics, individuals with incident AF ( n = 320 139) or cancer ( n = 472 745) were identified during the period 2015–19. Dutch inhabitants without a history of AF ( n = 320 135) or cancer ( n = 472 741) were matched as control cohorts by demographic characteristics. Prevalence of cancer/AF at baseline, 1-year risk of cancer/AF diagnosis, and their time trends were determined. The association of cancer/AF diagnosis with all-cause mortality among those with AF/cancer was estimated by using time-dependent Cox regression.

          Results

          The rate of prevalence of cancer in the AF cohort was 12.6% (increasing from 11.9% to 13.2%) compared with 5.6% in the controls; 1-year cancer risk was 2.5% (stable over years) compared with 1.8% in the controls [adjusted hazard ratio (aHR) 1.52, 95% confidence interval (CI) 1.46–1.58], which was similar by cancer type. The rate of prevalence of AF in the cancer cohort was 7.5% (increasing from 6.9% to 8.2%) compared with 4.3% in the controls; 1-year AF risk was 2.8% (stable over years) compared with 1.2% in the controls (aHR 2.78, 95% CI 2.69–2.87), but cancers of the oesophagus, lung, stomach, myeloma, and lymphoma were associated with higher hazards of AF than other cancer types. Both cancer diagnosed after incident AF (aHR 7.77, 95% CI 7.45–8.11) and AF diagnosed after incident cancer (aHR 2.55, 95% CI 2.47–2.63) were associated with all-cause mortality, but the strength of the association varied by cancer type.

          Conclusions

          Atrial fibrillation and cancer were associated bidirectionally and were increasingly coexisting, but AF risk varied by cancer type. Coexisting AF and cancer were negatively associated with survival.

          Structured Graphical Abstract

          Structured Graphical Abstract

          Prevalence, incidence, time trend, and association with all-cause mortality of coexisting atrial fibrillation and cancer in the Netherlands. AF, atrial fibrillation; aHR, adjusted hazard ratio; CI, confidence interval.

          Related collections

          Most cited references72

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            OUP accepted manuscript

            (2020)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Preoperative chemoradiotherapy for esophageal or junctional cancer.

              The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well established. We compared chemoradiotherapy followed by surgery with surgery alone in this patient population. We randomly assigned patients with resectable tumors to receive surgery alone or weekly administration of carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days per week), followed by surgery. From March 2004 through December 2008, we enrolled 368 patients, 366 of whom were included in the analysis: 275 (75%) had adenocarcinoma, 84 (23%) had squamous-cell carcinoma, and 7 (2%) had large-cell undifferentiated carcinoma. Of the 366 patients, 178 were randomly assigned to chemoradiotherapy followed by surgery, and 188 to surgery alone. The most common major hematologic toxic effects in the chemoradiotherapy-surgery group were leukopenia (6%) and neutropenia (2%); the most common major nonhematologic toxic effects were anorexia (5%) and fatigue (3%). Complete resection with no tumor within 1 mm of the resection margins (R0) was achieved in 92% of patients in the chemoradiotherapy-surgery group versus 69% in the surgery group (P<0.001). A pathological complete response was achieved in 47 of 161 patients (29%) who underwent resection after chemoradiotherapy. Postoperative complications were similar in the two treatment groups, and in-hospital mortality was 4% in both. Median overall survival was 49.4 months in the chemoradiotherapy-surgery group versus 24.0 months in the surgery group. Overall survival was significantly better in the chemoradiotherapy-surgery group (hazard ratio, 0.657; 95% confidence interval, 0.495 to 0.871; P=0.003). Preoperative chemoradiotherapy improved survival among patients with potentially curable esophageal or esophagogastric-junction cancer. The regimen was associated with acceptable adverse-event rates. (Funded by the Dutch Cancer Foundation [KWF Kankerbestrijding]; Netherlands Trial Register number, NTR487.).
                Bookmark

                Author and article information

                Contributors
                Journal
                Eur Heart J
                Eur Heart J
                eurheartj
                European Heart Journal
                Oxford University Press (UK )
                0195-668X
                1522-9645
                01 July 2024
                15 April 2024
                15 April 2024
                : 45
                : 25 , Focus Issue on Cardio-oncology, Ischaemic Heart Disease, and Heart Failure
                : 2201-2213
                Affiliations
                Department of Clinical Epidemiology, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden, The Netherlands
                Department of Clinical Epidemiology, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden, The Netherlands
                Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden, The Netherlands
                Department of Medical Oncology, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden, The Netherlands
                Department of Cardiology, Heart Lung Center, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden, The Netherlands
                Cardiovascular Imaging Research Center, Division of Cardiology, and Department of Radiology, Massachusetts General Hospital , 55 Fruit St, Boston, MA 02114, USA
                Department of Cardiology, Heart Lung Center, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden, The Netherlands
                Department of Medicine, Section of Thrombosis and Hemostasis, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden, The Netherlands
                Department of Medicine, Section of Thrombosis and Hemostasis, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden, The Netherlands
                Department of Clinical Epidemiology, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden, The Netherlands
                Department of Medicine, Section of Thrombosis and Hemostasis, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden, The Netherlands
                Author notes
                Corresponding author. Tel: +31 648921874, Email: q.chen@ 123456lumc.nl ; qingui4ch@ 123456gmail.com
                Author information
                https://orcid.org/0000-0001-9669-0007
                https://orcid.org/0000-0002-2296-1828
                https://orcid.org/0000-0001-7715-9536
                https://orcid.org/0000-0001-9961-0754
                https://orcid.org/0000-0003-4707-2303
                Article
                ehae222
                10.1093/eurheartj/ehae222
                11231645
                38619538
                11b46bbb-4c9d-454d-92f0-c9b49b18c8a7
                © The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

                History
                : 05 September 2023
                : 24 February 2024
                : 26 March 2024
                Page count
                Pages: 13
                Categories
                Clinical Research
                AcademicSubjects/MED00200
                Eurheartj/1
                Eurheartj/3
                Eurheartj/12

                Cardiovascular Medicine
                atrial fibrillation,neoplasms,prevalence,incidence,mortality
                Cardiovascular Medicine
                atrial fibrillation, neoplasms, prevalence, incidence, mortality

                Comments

                Comment on this article